Active, not recruitingPhase 3NCT06383403
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
Studying Primary biliary cholangitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ipsen
- Principal Investigator
- Ipsen Medical DirectorIpsen
- Intervention
- Elafibranor(drug)
- Enrollment
- 69 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (30)
- Southern California Research Center, Coronado, California, United States
- Topgraphy Health, Inc., Los Angeles, California, United States
- University of California, Davis, Sacramento, California, United States
- Stanford University Medical Center, Stanford, California, United States
- Peak Gastroenterology Associates, Colorado Springs, Colorado, United States
- Rocky Mountain Gastroenterology, Littleton, Colorado, United States
- International Center for Research, Tampa, Florida, United States
- Delta Research Partners, LLC, West Monroe, Louisiana, United States
- University of Michigan Health System, Ann Arbor, Michigan, United States
- Huron Gastroenterology Associates - Center for Digestive Care, Ypsilanti, Michigan, United States
- South Denver Gastroenterology,P.C., Englewood, New Jersey, United States
- Southwest Gastroenterology Associates, PC (SWGA), Albuquerque, New Mexico, United States
- Northwell Health Center for Liver Disease and Transplantation, Manhasset, New York, United States
- Charlotte Gastroenterology & Hepatology, PLLC, Charlotte, North Carolina, United States
- Coastal Research Institute, Fayetteville, North Carolina, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06383403 on ClinicalTrials.govOther trials for Primary biliary cholangitis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07449793Biochemical Response and Clinical Outcomes in Patients With PBCRenJi Hospital
- RECRUITINGPHASE3NCT07296458FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC TherapyXijing Hospital of Digestive Diseases
- RECRUITINGPHASE3NCT07282353A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCACascade Pharmaceuticals, Inc
- RECRUITINGNCT07205874Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)Hospital Universitario La Paz
- ACTIVE NOT RECRUITINGNCT07049887A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)Ipsen
- RECRUITINGNCT07149675PBC Long-term Outcomes StudyBeijing Friendship Hospital
- RECRUITINGEARLY PHASE1NCT07104201Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)Xijing Hospital of Digestive Diseases
- RECRUITINGNANCT06861465EMPower MechanismsUniversity of Alberta